<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 19:04:58 -0700</creation_date>
  <update_date>2013-01-15 19:04:58 -0700</update_date>
  <accession>HMDBP02400</accession>
  <secondary_accessions>
    <accession>7893</accession>
  </secondary_accessions>
  <protein_type>Enzyme</protein_type>
  <synonyms>
    <synonym>5-HT-1B</synonym>
    <synonym>5-HT-1D-beta</synonym>
    <synonym>5-HT1B</synonym>
    <synonym>S12</synonym>
    <synonym>Serotonin 1D beta receptor</synonym>
    <synonym>Serotonin receptor 1B</synonym>
  </synonyms>
  <gene_name>HTR1B</gene_name>
  <general_function>Involved in G-protein coupled receptor protein signaling pathway</general_function>
  <specific_function>This is one of the several different receptors for 5- hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that inhibit adenylate cyclase activity</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB05016</accession>
      <name>Venlafaxine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05037</accession>
      <name>Sumatriptan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00259</accession>
      <name>Serotonin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01849</accession>
      <name>Propranolol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13919</accession>
      <name>N-Desmethyleletriptan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14391</accession>
      <name>Ziprasidone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14393</accession>
      <name>Cabergoline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14413</accession>
      <name>Ropinirole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14460</accession>
      <name>Zolmitriptan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14465</accession>
      <name>Dihydroergotamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14557</accession>
      <name>Pramipexole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14727</accession>
      <name>Lisuride</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14834</accession>
      <name>Ergotamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14852</accession>
      <name>Apomorphine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15054</accession>
      <name>Almotriptan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15087</accession>
      <name>Naratriptan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15088</accession>
      <name>Rizatriptan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15095</accession>
      <name>Pindolol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15133</accession>
      <name>Frovatriptan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15317</accession>
      <name>Pergolide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15331</accession>
      <name>Bromocriptine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05042</accession>
      <name>Aripiprazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15464</accession>
      <name>Yohimbine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15696</accession>
      <name>Bopindolol</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>process</category>
      <description>signaling</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cell surface receptor linked signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>g-protein coupled receptor protein signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intrinsic to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>integral to membrane</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Cell membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:6</chromosome_location>
    <locus>6q13</locus>
    <gene_sequence>&gt;1173 bp
ATGGAGGAACCGGGTGCTCAGTGCGCTCCACCGCCGCCCGCGGGCTCCGAGACCTGGGTT
CCTCAAGCCAACTTATCCTCTGCTCCCTCCCAAAACTGCAGCGCCAAGGACTACATTTAC
CAGGACTCCATCTCCCTACCCTGGAAAGTACTGCTGGTTATGCTATTGGCGCTCATCACC
TTGGCCACCACGCTCTCCAATGCCTTTGTGATTGCCACAGTGTACCGGACCCGGAAACTG
CACACCCCGGCTAACTACCTGATCGCCTCTCTGGCAGTCACCGACCTGCTTGTGTCCATC
CTGGTGATGCCCATCAGCACCATGTACACTGTCACCGGCCGCTGGACACTGGGCCAGGTG
GTCTGTGACTTCTGGCTGTCGTCGGACATCACTTGTTGCACTGCCTCCATCCTGCACCTC
TGTGTCATCGCCCTGGACCGCTACTGGGCCATCACGGACGCCGTGGAGTACTCAGCTAAA
AGGACTCCCAAGAGGGCGGCGGTCATGATCGCGCTGGTGTGGGTCTTCTCCATCTCTATC
TCGCTGCCGCCCTTCTTCTGGCGTCAGGCTAAGGCCGAAGAGGAGGTGTCGGAATGCGTG
GTGAACACCGACCACATCCTCTACACGGTCTACTCCACGGTGGGTGCTTTCTACTTCCCC
ACCCTGCTCCTCATCGCCCTCTATGGCCGCATCTACGTAGAAGCCCGCTCCCGGATTTTG
AAACAGACGCCCAACAGGACCGGCAAGCGCTTGACCCGAGCCCAGCTGATAACCGACTCC
CCCGGGTCCACGTCCTCGGTCACCTCTATTAACTCGCGGGTTCCCGACGTGCCCAGCGAA
TCCGGATCTCCTGTGTATGTGAACCAAGTCAAAGTGCGAGTCTCCGACGCCCTGCTGGAA
AAGAAGAAACTCATGGCCGCTAGGGAGCGCAAAGCCACCAAGACCCTAGGGATCATTTTG
GGAGCCTTTATTGTGTGTTGGCTACCCTTCTTCATCATCTCCCTAGTGATGCCTATCTGC
AAAGATGCCTGCTGGTTCCACCTAGCCATCTTTGACTTCTTCACATGGCTGGGCTATCTC
AACTCCCTCATCAACCCCATAATCTATACCATGTCCAATGAGGACTTTAAACAAGCATTC
CATAAACTGATACGTTTTAAGTGCACAAGTTGA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>390</residue_number>
    <molecular_weight>43567.5</molecular_weight>
    <theoretical_pi>8.82</theoretical_pi>
    <pfams>
      <pfam>
        <name>7tm_1</name>
        <pfam_id>PF00001</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>50-73</region>
      <region>87-109</region>
      <region>120-145</region>
      <region>166-187</region>
      <region>206-229</region>
      <region>316-340</region>
      <region>348-373</region>
    </transmembrane_regions>
    <signal_regions>
      <region>None</region>
    </signal_regions>
    <protein_sequence>&gt;5-hydroxytryptamine receptor 1B
MEEPGAQCAPPPPAGSETWVPQANLSSAPSQNCSAKDYIYQDSISLPWKVLLVMLLALIT
LATTLSNAFVIATVYRTRKLHTPANYLIASLAVTDLLVSILVMPISTMYTVTGRWTLGQV
VCDFWLSSDITCCTASILHLCVIALDRYWAITDAVEYSAKRTPKRAAVMIALVWVFSISI
SLPPFFWRQAKAEEEVSECVVNTDHILYTVYSTVGAFYFPTLLLIALYGRIYVEARSRIL
KQTPNRTGKRLTRAQLITDSPGSTSSVTSINSRVPDVPSESGSPVYVNQVKVRVSDALLE
KKKLMAARERKATKTLGIILGAFIVCWLPFFIISLVMPICKDACWFHLAIFDFFTWLGYL
NSLINPIIYTMSNEDFKQAFHKLIRFKCTS</protein_sequence>
  </protein_properties>
  <genbank_protein_id/>
  <uniprot_id>P28222</uniprot_id>
  <uniprot_name>5HT1B_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>M81590</genbank_gene_id>
  <genecard_id>HTR1B</genecard_id>
  <geneatlas_id>HTR1B</geneatlas_id>
  <hgnc_id>HGNC:5287</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Hamblin MW, Metcalf MA, McGuffin RW, Karpells S: Molecular cloning and functional characterization of a human 5-HT1B serotonin receptor: a homologue of the rat 5-HT1B receptor with 5-HT1D-like pharmacological specificity. Biochem Biophys Res Commun. 1992 Apr 30;184(2):752-9.</reference_text>
      <pubmed_id>1315531</pubmed_id>
    </reference>
    <reference>
      <reference_text>Mochizuki D, Yuyama Y, Tsujita R, Komaki H, Sagai H: Cloning and expression of the human 5-HT1B-type receptor gene.  Biochem Biophys Res Commun. 1992 Jun 15;185(2):517-23.</reference_text>
      <pubmed_id>1610347</pubmed_id>
    </reference>
    <reference>
      <reference_text>Jin H, Oksenberg D, Ashkenazi A, Peroutka SJ, Duncan AM, Rozmahel R, Yang Y, Mengod G, Palacios JM, O'Dowd BF: Characterization of the human 5-hydroxytryptamine1B receptor.  J Biol Chem. 1992 Mar 25;267(9):5735-8.</reference_text>
      <pubmed_id>1348246</pubmed_id>
    </reference>
    <reference>
      <reference_text>Levy FO, Gudermann T, Perez-Reyes E, Birnbaumer M, Kaumann AJ, Birnbaumer L: Molecular cloning of a human serotonin receptor (S12) with a pharmacological profile resembling that of the 5-HT1D subtype. J Biol Chem. 1992 Apr 15;267(11):7553-62.</reference_text>
      <pubmed_id>1559993</pubmed_id>
    </reference>
    <reference>
      <reference_text>Weinshank RL, Zgombick JM, Macchi MJ, Branchek TA, Hartig PR: Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1D alpha and 5-HT1D beta. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3630-4.</reference_text>
      <pubmed_id>1565658</pubmed_id>
    </reference>
    <reference>
      <reference_text>Demchyshyn L, Sunahara RK, Miller K, Teitler M, Hoffman BJ, Kennedy JL, Seeman P, Van Tol HH, Niznik HB: A human serotonin 1D receptor variant (5HT1D beta) encoded by an intronless gene on chromosome 6. Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5522-6.</reference_text>
      <pubmed_id>1351684</pubmed_id>
    </reference>
    <reference>
      <reference_text>Veldman SA, Bienkowski MJ: Cloning and pharmacological characterization of a novel human 5-hydroxytryptamine1D receptor subtype. Mol Pharmacol. 1992 Sep;42(3):439-44.</reference_text>
      <pubmed_id>1328844</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kitano T, Liu YH, Ueda S, Saitou N: Human-specific amino acid changes found in 103 protein-coding genes.  Mol Biol Evol. 2004 May;21(5):936-44. Epub 2004 Mar 10.</reference_text>
      <pubmed_id>15014171</pubmed_id>
    </reference>
    <reference>
      <reference_text>Mungall AJ, Palmer SA, Sims SK, Edwards CA, Ashurst JL, Wilming L, Jones MC, Horton R, Hunt SE, Scott CE, Gilbert JG, Clamp ME, Bethel G, Milne S, Ainscough R, Almeida JP, Ambrose KD, Andrews TD, Ashwell RI, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Barker DJ, Barlow KF, Bates K, Beare DM, Beasley H, Beasley O, Bird CP, Blakey S, Bray-Allen S, Brook J, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Carder C, Carter NP, Chapman JC, Clark SY, Clark G, Clee CM, Clegg S, Cobley V, Collier RE, Collins JE, Colman LK, Corby NR, Coville GJ, Culley KM, Dhami P, Davies J, Dunn M, Earthrowl ME, Ellington AE, Evans KA, Faulkner L, Francis MD, Frankish A, Frankland J, French L, Garner P, Garnett J, Ghori MJ, Gilby LM, Gillson CJ, Glithero RJ, Grafham DV, Grant M, Gribble S, Griffiths C, Griffiths M, Hall R, Halls KS, Hammond S, Harley JL, Hart EA, Heath PD, Heathcott R, Holmes SJ, Howden PJ, Howe KL, Howell GR, Huckle E, Humphray SJ, Humphries MD, Hunt AR, Johnson CM, Joy AA, Kay M, Keenan SJ, Kimberley AM, King A, Laird GK, Langford C, Lawlor S, Leongamornlert DA, Leversha M, Lloyd CR, Lloyd DM, Loveland JE, Lovell J, Martin S, Mashreghi-Mohammadi M, Maslen GL, Matthews L, McCann OT, McLaren SJ, McLay K, McMurray A, Moore MJ, Mullikin JC, Niblett D, Nickerson T, Novik KL, Oliver K, Overton-Larty EK, Parker A, Patel R, Pearce AV, Peck AI, Phillimore B, Phillips S, Plumb RW, Porter KM, Ramsey Y, Ranby SA, Rice CM, Ross MT, Searle SM, Sehra HK, Sheridan E, Skuce CD, Smith S, Smith M, Spraggon L, Squares SL, Steward CA, Sycamore N, Tamlyn-Hall G, Tester J, Theaker AJ, Thomas DW, Thorpe A, Tracey A, Tromans A, Tubby B, Wall M, Wallis JM, West AP, White SS, Whitehead SL, Whittaker H, Wild A, Willey DJ, Wilmer TE, Wood JM, Wray PW, Wyatt JC, Young L, Younger RM, Bentley DR, Coulson A, Durbin R, Hubbard T, Sulston JE, Dunham I, Rogers J, Beck S: The DNA sequence and analysis of human chromosome 6.  Nature. 2003 Oct 23;425(6960):805-11.</reference_text>
      <pubmed_id>14574404</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ng GY, George SR, Zastawny RL, Caron M, Bouvier M, Dennis M, O'Dowd BF: Human serotonin1B receptor expression in Sf9 cells: phosphorylation, palmitoylation, and adenylyl cyclase inhibition. Biochemistry. 1993 Nov 2;32(43):11727-33.</reference_text>
      <pubmed_id>8218242</pubmed_id>
    </reference>
    <reference>
      <reference_text>Nothen MM, Erdmann J, Shimron-Abarbanell D, Propping P: Identification of genetic variation in the human serotonin 1D beta receptor gene. Biochem Biophys Res Commun. 1994 Dec 15;205(2):1194-200.</reference_text>
      <pubmed_id>7802650</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethyleletriptan</name>
        <accession>HMDB13919</accession>
      </metabolite>
      <reference>
        <reference_text>Napier C, Stewart M, Melrose H, Hopkins B, McHarg A, Wallis R: Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol. 1999 Mar 5;368(2-3):259-68.</reference_text>
        <pubmed_id>10193663</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethyleletriptan</name>
        <accession>HMDB13919</accession>
      </metabolite>
      <reference>
        <reference_text>van den Broek RW, MaassenVanDenBrink A, de Vries R, Bogers AJ, Stegmann AP, Avezaat CJ, Saxena PR: Pharmacological analysis of contractile effects of eletriptan and sumatriptan on human isolated blood vessels. Eur J Pharmacol. 2000 Oct 27;407(1-2):165-73.</reference_text>
        <pubmed_id>11050304</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethyleletriptan</name>
        <accession>HMDB13919</accession>
      </metabolite>
      <reference>
        <reference_text>Knyihar-Csillik E, Tajti J, Csillik AE, Chadaide Z, Mihaly A, Vecsei L: Effects of eletriptan on the peptidergic innervation of the cerebral dura mater and trigeminal ganglion, and on the expression of c-fos and c-jun in the trigeminal complex of the rat in an experimental migraine model. Eur J Neurosci. 2000 Nov;12(11):3991-4002.</reference_text>
        <pubmed_id>11069595</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethyleletriptan</name>
        <accession>HMDB13919</accession>
      </metabolite>
      <reference>
        <reference_text>Johnson DE, Rollema H, Schmidt AW, McHarg AD: Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan and sumatriptan in rat brain. Eur J Pharmacol. 2001 Aug 17;425(3):203-10.</reference_text>
        <pubmed_id>11513839</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethyleletriptan</name>
        <accession>HMDB13919</accession>
      </metabolite>
      <reference>
        <reference_text>Lambert GA, Boers PM, Hoskin KL, Donaldson C, Zagami AS: Suppression by eletriptan of the activation of trigeminovascular sensory neurons by glyceryl trinitrate. Brain Res. 2002 Oct 25;953(1-2):181-8.</reference_text>
        <pubmed_id>12384251</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethyleletriptan</name>
        <accession>HMDB13919</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ziprasidone</name>
        <accession>HMDB14391</accession>
      </metabolite>
      <reference>
        <reference_text>Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11.</reference_text>
        <pubmed_id>17848919</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cabergoline</name>
        <accession>HMDB14393</accession>
      </metabolite>
      <reference>
        <reference_text>Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists.  Curr Top Med Chem. 2008;8(12):1049-67.</reference_text>
        <pubmed_id>18691132</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cabergoline</name>
        <accession>HMDB14393</accession>
      </metabolite>
      <reference>
        <reference_text>Lam YW: Clinical pharmacology of dopamine agonists.  Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S.</reference_text>
        <pubmed_id>10641988</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ropinirole</name>
        <accession>HMDB14413</accession>
      </metabolite>
      <reference>
        <reference_text>Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists.  Curr Top Med Chem. 2008;8(12):1049-67.</reference_text>
        <pubmed_id>18691132</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zolmitriptan</name>
        <accession>HMDB14460</accession>
      </metabolite>
      <reference>
        <reference_text>Le Grand B, Panissie A, Perez M, Pauwels PJ, John GW: Zolmitriptan stimulates a Ca(2+)-dependent K(+) current in C6 glioma cells stably expressing recombinant human 5-HT(1B) receptors. Eur J Pharmacol. 2000 Jun 2;397(2-3):297-302.</reference_text>
        <pubmed_id>10844127</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zolmitriptan</name>
        <accession>HMDB14460</accession>
      </metabolite>
      <reference>
        <reference_text>Johnson DE, Rollema H, Schmidt AW, McHarg AD: Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan and sumatriptan in rat brain. Eur J Pharmacol. 2001 Aug 17;425(3):203-10.</reference_text>
        <pubmed_id>11513839</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zolmitriptan</name>
        <accession>HMDB14460</accession>
      </metabolite>
      <reference>
        <reference_text>de Almeida RM, Nikulina EM, Faccidomo S, Fish EW, Miczek KA: Zolmitriptan--a 5-HT1B/D agonist, alcohol, and aggression in mice.  Psychopharmacology (Berl). 2001 Sep;157(2):131-41.</reference_text>
        <pubmed_id>11594437</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zolmitriptan</name>
        <accession>HMDB14460</accession>
      </metabolite>
      <reference>
        <reference_text>Reuter U, Salomone S, Ickenstein GW, Waeber C: Effects of chronic sumatriptan and zolmitriptan treatment on 5-HT receptor expression and function in rats. Cephalalgia. 2004 May;24(5):398-407.</reference_text>
        <pubmed_id>15096229</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zolmitriptan</name>
        <accession>HMDB14460</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zolmitriptan</name>
        <accession>HMDB14460</accession>
      </metabolite>
      <reference>
        <reference_text>Whale R, Bhagwagar Z, Cowen PJ: Zolmitriptan-induced growth hormone release in humans: mediation by 5-HT1D receptors? Psychopharmacology (Berl). 1999 Jul;145(2):223-6.</reference_text>
        <pubmed_id>10463324</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zolmitriptan</name>
        <accession>HMDB14460</accession>
      </metabolite>
      <reference>
        <reference_text>Hargreaves RJ, Shepheard SL: Pathophysiology of migraine--new insights.  Can J Neurol Sci. 1999 Nov;26 Suppl 3:S12-9.</reference_text>
        <pubmed_id>10563228</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zolmitriptan</name>
        <accession>HMDB14460</accession>
      </metabolite>
      <reference>
        <reference_text>Gowin JL, Swann AC, Moeller FG, Lane SD: Zolmitriptan and human aggression: interaction with alcohol.  Psychopharmacology (Berl). 2010 Jul;210(4):521-31. Epub 2010 Apr 21.</reference_text>
        <pubmed_id>20407761</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zolmitriptan</name>
        <accession>HMDB14460</accession>
      </metabolite>
      <reference>
        <reference_text>Pascual J: [Mechanism of action of zolmitriptan].  Neurologia. 1998 Oct;13 Suppl 2:9-15.</reference_text>
        <pubmed_id>9859690</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zolmitriptan</name>
        <accession>HMDB14460</accession>
      </metabolite>
      <reference>
        <reference_text>Martin GR: Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine. Cephalalgia. 1997 Oct;17 Suppl 18:4-14.</reference_text>
        <pubmed_id>9399012</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dihydroergotamine</name>
        <accession>HMDB14465</accession>
      </metabolite>
      <reference>
        <reference_text>Willems EW, Trion M, De Vries P, Heiligers JP, Villalon CM, Saxena PR: Pharmacological evidence that alpha1-and alpha2-adrenoceptors mediate vasoconstriction of carotid arteriovenous anastomoses in anaesthetized pigs. Br J Pharmacol. 1999 Jul;127(5):1263-71.</reference_text>
        <pubmed_id>10455274</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dihydroergotamine</name>
        <accession>HMDB14465</accession>
      </metabolite>
      <reference>
        <reference_text>Villalon CM, Centurion D, Willems EW, Arulmani U, Saxena PR, Valdivia LF: 5-HT1B receptors and alpha 2A/2C-adrenoceptors mediate external carotid vasoconstriction to dihydroergotamine. Eur J Pharmacol. 2004 Jan 26;484(2-3):287-90.</reference_text>
        <pubmed_id>14744615</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dihydroergotamine</name>
        <accession>HMDB14465</accession>
      </metabolite>
      <reference>
        <reference_text>Buzzi MG, Moskowitz MA: Evidence for 5-HT1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine. Cephalalgia. 1991 Sep;11(4):165-8.</reference_text>
        <pubmed_id>1660351</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dihydroergotamine</name>
        <accession>HMDB14465</accession>
      </metabolite>
      <reference>
        <reference_text>Yu XJ, Waeber C, Castanon N, Scearce K, Hen R, Macor JE, Chauveau J, Moskowitz MA: 5-Carboxamido-tryptamine, CP-122,288 and dihydroergotamine but not sumatriptan, CP-93,129, and serotonin-5-O-carboxymethyl-glycyl -tyrosinamide block dural plasma protein extravasation in knockout mice that lack 5-hydroxytryptamine1B receptors. Mol Pharmacol. 1996 May;49(5):761-5.</reference_text>
        <pubmed_id>8622623</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dihydroergotamine</name>
        <accession>HMDB14465</accession>
      </metabolite>
      <reference>
        <reference_text>Pauwels PJ, Palmier C, Dupuis DS, Colpaert FC: Interaction of 5-HT1B/D ligands with recombinant h 5-HT1A receptors: intrinsic activity and modulation by G-protein activation state. Naunyn Schmiedebergs Arch Pharmacol. 1998 May;357(5):490-9.</reference_text>
        <pubmed_id>9650800</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pramipexole</name>
        <accession>HMDB14557</accession>
      </metabolite>
      <reference>
        <reference_text>Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists.  Curr Top Med Chem. 2008;8(12):1049-67.</reference_text>
        <pubmed_id>18691132</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pramipexole</name>
        <accession>HMDB14557</accession>
      </metabolite>
      <reference>
        <reference_text>Lam YW: Clinical pharmacology of dopamine agonists.  Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S.</reference_text>
        <pubmed_id>10641988</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lisuride</name>
        <accession>HMDB14727</accession>
      </metabolite>
      <reference>
        <reference_text>Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists.  Curr Top Med Chem. 2008;8(12):1049-67.</reference_text>
        <pubmed_id>18691132</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ergotamine</name>
        <accession>HMDB14834</accession>
      </metabolite>
      <reference>
        <reference_text>Villalon CM, De Vries P, Rabelo G, Centurion D, Sanchez-Lopez A, Saxena P: Canine external carotid vasoconstriction to methysergide, ergotamine and dihydroergotamine: role of 5-HT1B/1D receptors and alpha2-adrenoceptors. Br J Pharmacol. 1999 Feb;126(3):585-94.</reference_text>
        <pubmed_id>10188968</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ergotamine</name>
        <accession>HMDB14834</accession>
      </metabolite>
      <reference>
        <reference_text>Willems EW, Trion M, De Vries P, Heiligers JP, Villalon CM, Saxena PR: Pharmacological evidence that alpha1-and alpha2-adrenoceptors mediate vasoconstriction of carotid arteriovenous anastomoses in anaesthetized pigs. Br J Pharmacol. 1999 Jul;127(5):1263-71.</reference_text>
        <pubmed_id>10455274</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ergotamine</name>
        <accession>HMDB14834</accession>
      </metabolite>
      <reference>
        <reference_text>Cohen ML, Schenck K: Contractile responses to sumatriptan and ergotamine in the rabbit saphenous vein: effect of selective 5-HT(1F) receptor agonists and PGF(2alpha). Br J Pharmacol. 2000 Oct;131(3):562-8.</reference_text>
        <pubmed_id>11015308</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ergotamine</name>
        <accession>HMDB14834</accession>
      </metabolite>
      <reference>
        <reference_text>Valdivia LF, Centurion D, Arulmani U, Saxena PR, Villalon CM: 5-HT1B receptors, alpha2A/2C- and, to a lesser extent, alpha1-adrenoceptors mediate the external carotid vasoconstriction to ergotamine in vagosympathectomised dogs. Naunyn Schmiedebergs Arch Pharmacol. 2004 Jul;370(1):46-53. Epub 2004 Jun 29.</reference_text>
        <pubmed_id>15224175</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Apomorphine</name>
        <accession>HMDB14852</accession>
      </metabolite>
      <reference>
        <reference_text>Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists.  Curr Top Med Chem. 2008;8(12):1049-67.</reference_text>
        <pubmed_id>18691132</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Almotriptan</name>
        <accession>HMDB15054</accession>
      </metabolite>
      <reference>
        <reference_text>Napier C, Stewart M, Melrose H, Hopkins B, McHarg A, Wallis R: Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol. 1999 Mar 5;368(2-3):259-68.</reference_text>
        <pubmed_id>10193663</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Almotriptan</name>
        <accession>HMDB15054</accession>
      </metabolite>
      <reference>
        <reference_text>Fleishaker JC, Sisson TA, Carel BJ, Azie NE: Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers. Clin Pharmacol Ther. 2000 May;67(5):498-503.</reference_text>
        <pubmed_id>10824628</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Almotriptan</name>
        <accession>HMDB15054</accession>
      </metabolite>
      <reference>
        <reference_text>van den Broek RW, MaassenVanDenBrink A, de Vries R, Bogers AJ, Stegmann AP, Avezaat CJ, Saxena PR: Pharmacological analysis of contractile effects of eletriptan and sumatriptan on human isolated blood vessels. Eur J Pharmacol. 2000 Oct 27;407(1-2):165-73.</reference_text>
        <pubmed_id>11050304</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Almotriptan</name>
        <accession>HMDB15054</accession>
      </metabolite>
      <reference>
        <reference_text>Knyihar-Csillik E, Tajti J, Csillik AE, Chadaide Z, Mihaly A, Vecsei L: Effects of eletriptan on the peptidergic innervation of the cerebral dura mater and trigeminal ganglion, and on the expression of c-fos and c-jun in the trigeminal complex of the rat in an experimental migraine model. Eur J Neurosci. 2000 Nov;12(11):3991-4002.</reference_text>
        <pubmed_id>11069595</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Almotriptan</name>
        <accession>HMDB15054</accession>
      </metabolite>
      <reference>
        <reference_text>Bou J, Domenech T, Puig J, Heredia A, Gras J, Fernandez-Forner D, Beleta J, Palacios JM: Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine. Eur J Pharmacol. 2000 Dec 20;410(1):33-41.</reference_text>
        <pubmed_id>11134654</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Almotriptan</name>
        <accession>HMDB15054</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naratriptan</name>
        <accession>HMDB15087</accession>
      </metabolite>
      <reference>
        <reference_text>Akin D, Onaran HO, Gurdal H: Agonist-directed trafficking explaining the difference between response pattern of naratriptan and sumatriptan in rabbit common carotid artery. Br J Pharmacol. 2002 May;136(2):171-6.</reference_text>
        <pubmed_id>12010764</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naratriptan</name>
        <accession>HMDB15087</accession>
      </metabolite>
      <reference>
        <reference_text>Hoskin KL, Lambert GA, Donaldson C, Zagami AS: The 5-hydroxytryptamine1B/1D/1F receptor agonists eletriptan and naratriptan inhibit trigeminovascular input to the nucleus tractus solitarius in the cat. Brain Res. 2004 Feb 13;998(1):91-9.</reference_text>
        <pubmed_id>14725972</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naratriptan</name>
        <accession>HMDB15087</accession>
      </metabolite>
      <reference>
        <reference_text>Boers PM, Donaldson C, Zagami AS, Lambert GA: Naratriptan has a selective inhibitory effect on trigeminovascular neurones at central 5-HT1A and 5-HT(1B/1D) receptors in the cat: implications for migraine therapy. Cephalalgia. 2004 Feb;24(2):99-109.</reference_text>
        <pubmed_id>14728705</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naratriptan</name>
        <accession>HMDB15087</accession>
      </metabolite>
      <reference>
        <reference_text>Pauwels PJ, Palmier C, Dupuis DS, Colpaert FC: Interaction of 5-HT1B/D ligands with recombinant h 5-HT1A receptors: intrinsic activity and modulation by G-protein activation state. Naunyn Schmiedebergs Arch Pharmacol. 1998 May;357(5):490-9.</reference_text>
        <pubmed_id>9650800</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naratriptan</name>
        <accession>HMDB15087</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naratriptan</name>
        <accession>HMDB15087</accession>
      </metabolite>
      <reference>
        <reference_text>Johnston MM, Rapoport AM: Triptans for the management of migraine.  Drugs. 2010 Aug 20;70(12):1505-18. doi: 10.2165/11537990-000000000-00000.</reference_text>
        <pubmed_id>20687618</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naratriptan</name>
        <accession>HMDB15087</accession>
      </metabolite>
      <reference>
        <reference_text>Dulli DA: Naratriptan: an alternative for migraine.  Ann Pharmacother. 1999 Jun;33(6):704-11.</reference_text>
        <pubmed_id>10410185</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naratriptan</name>
        <accession>HMDB15087</accession>
      </metabolite>
      <reference>
        <reference_text>Tfelt-Hansen P, De Vries P, Saxena PR: Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000 Dec;60(6):1259-87.</reference_text>
        <pubmed_id>11152011</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naratriptan</name>
        <accession>HMDB15087</accession>
      </metabolite>
      <reference>
        <reference_text>Massiou H: Naratriptan.  Curr Med Res Opin. 2001;17 Suppl 1:s51-3.</reference_text>
        <pubmed_id>12463278</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naratriptan</name>
        <accession>HMDB15087</accession>
      </metabolite>
      <reference>
        <reference_text>Lambert GA: Preclinical neuropharmacology of naratriptan.  CNS Drug Rev. 2005 Autumn;11(3):289-316.</reference_text>
        <pubmed_id>16389295</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rizatriptan</name>
        <accession>HMDB15088</accession>
      </metabolite>
      <reference>
        <reference_text>Wellington K, Plosker GL: Rizatriptan: an update of its use in the management of migraine.  Drugs. 2002;62(10):1539-74.</reference_text>
        <pubmed_id>12093318</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rizatriptan</name>
        <accession>HMDB15088</accession>
      </metabolite>
      <reference>
        <reference_text>Wellington K, Jarvis B: Spotlight on rizatriptan in migraine.  CNS Drugs. 2002;16(10):715-20.</reference_text>
        <pubmed_id>12269863</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rizatriptan</name>
        <accession>HMDB15088</accession>
      </metabolite>
      <reference>
        <reference_text>Ikemoto F, Toru T, Aijima H, Natsumeda Y: [Rizatriptan (Maxalt), a new entity of triptan for migraine: pharmacology and therapeutic relevance]. Nihon Yakurigaku Zasshi. 2004 Apr;123(4):295-302.</reference_text>
        <pubmed_id>15056946</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rizatriptan</name>
        <accession>HMDB15088</accession>
      </metabolite>
      <reference>
        <reference_text>Pauwels PJ, Palmier C, Dupuis DS, Colpaert FC: Interaction of 5-HT1B/D ligands with recombinant h 5-HT1A receptors: intrinsic activity and modulation by G-protein activation state. Naunyn Schmiedebergs Arch Pharmacol. 1998 May;357(5):490-9.</reference_text>
        <pubmed_id>9650800</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rizatriptan</name>
        <accession>HMDB15088</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rizatriptan</name>
        <accession>HMDB15088</accession>
      </metabolite>
      <reference>
        <reference_text>Williamson DJ, Hill RG, Shepheard SL, Hargreaves RJ: The anti-migraine 5-HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs. Br J Pharmacol. 2001 Aug;133(7):1029-34.</reference_text>
        <pubmed_id>11487512</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rizatriptan</name>
        <accession>HMDB15088</accession>
      </metabolite>
      <reference>
        <reference_text>Wackenfors A, Jarvius M, Ingemansson R, Edvinsson L, Malmsjo M: Triptans induce vasoconstriction of human arteries and veins from the thoracic wall. J Cardiovasc Pharmacol. 2005 May;45(5):476-84.</reference_text>
        <pubmed_id>15821444</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pindolol</name>
        <accession>HMDB15095</accession>
      </metabolite>
      <reference>
        <reference_text>Dawson LA, Nguyen HQ: The role of 5-HT(1A) and 5-HT(1B/1D) receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: the mechanism of action of (+/-)pindolol. Neuropharmacology. 2000 Apr 3;39(6):1044-52.</reference_text>
        <pubmed_id>10727715</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pindolol</name>
        <accession>HMDB15095</accession>
      </metabolite>
      <reference>
        <reference_text>Ariani K, Hamblin MW, Tan GL, Stratford CA, Ciaranello RD: G protein dependent alterations in [125I]iodocyanopindolol and +/- cyanopindolol binding at 5-HT1B binding sites in rat brain membranes. Neurochem Res. 1989 Sep;14(9):835-43.</reference_text>
        <pubmed_id>2512511</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pindolol</name>
        <accession>HMDB15095</accession>
      </metabolite>
      <reference>
        <reference_text>Leonhardt S, Herrick-Davis K, Titeler M: Detection of a novel serotonin receptor subtype (5-HT1E) in human brain: interaction with a GTP-binding protein. J Neurochem. 1989 Aug;53(2):465-71.</reference_text>
        <pubmed_id>2664084</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pindolol</name>
        <accession>HMDB15095</accession>
      </metabolite>
      <reference>
        <reference_text>Herrick-Davis K, Titeler M, Leonhardt S, Struble R, Price D: Serotonin 5-HT1D receptors in human prefrontal cortex and caudate: interaction with a GTP binding protein. J Neurochem. 1988 Dec;51(6):1906-12.</reference_text>
        <pubmed_id>3141589</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pindolol</name>
        <accession>HMDB15095</accession>
      </metabolite>
      <reference>
        <reference_text>Terron JA, Lopez-Munoz FJ, Hong E, Villalon CM: 2-(2-Aminoethyl)-quinoline (D-1997): a novel agonist at 5-hydroxytryptamine1-like receptors in the canine basilar artery. Arch Int Pharmacodyn Ther. 1994 Jan-Feb;327(1):56-68.</reference_text>
        <pubmed_id>7944828</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Frovatriptan</name>
        <accession>HMDB15133</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Frovatriptan</name>
        <accession>HMDB15133</accession>
      </metabolite>
      <reference>
        <reference_text>Balbisi EA: Frovatriptan succinate, a 5-HT1B/1D receptor agonist for migraine.  Int J Clin Pract. 2004 Jul;58(7):695-705.</reference_text>
        <pubmed_id>15311727</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Frovatriptan</name>
        <accession>HMDB15133</accession>
      </metabolite>
      <reference>
        <reference_text>Comer MB: Pharmacology of the selective 5-HT(1B/1D) agonist frovatriptan.  Headache. 2002 Apr;42 Suppl 2:S47-53.</reference_text>
        <pubmed_id>12028320</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Frovatriptan</name>
        <accession>HMDB15133</accession>
      </metabolite>
      <reference>
        <reference_text>Parsons AA, Raval P, Smith S, Tilford N, King FD, Kaumann AJ, Hunter J: Effects of the novel high-affinity 5-HT(1B/1D)-receptor ligand frovatriptan in human isolated basilar and coronary arteries. J Cardiovasc Pharmacol. 1998 Aug;32(2):220-4.</reference_text>
        <pubmed_id>9700983</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Frovatriptan</name>
        <accession>HMDB15133</accession>
      </metabolite>
      <reference>
        <reference_text>Easthope SE, Goa KL: Frovatriptan.  CNS Drugs. 2001;15(12):969-76; discussion 977-8.</reference_text>
        <pubmed_id>11735616</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Frovatriptan</name>
        <accession>HMDB15133</accession>
      </metabolite>
      <reference>
        <reference_text>Dodick DW, Sandrini G, Williams P: Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine. CNS Drugs. 2007;21(1):73-82.</reference_text>
        <pubmed_id>17190530</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Frovatriptan</name>
        <accession>HMDB15133</accession>
      </metabolite>
      <reference>
        <reference_text>Tfelt-Hansen P, De Vries P, Saxena PR: Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000 Dec;60(6):1259-87.</reference_text>
        <pubmed_id>11152011</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Frovatriptan</name>
        <accession>HMDB15133</accession>
      </metabolite>
      <reference>
        <reference_text>Deleu D, Hanssens Y: Current and emerging second-generation triptans in acute migraine therapy: a comparative review. J Clin Pharmacol. 2000 Jul;40(7):687-700.</reference_text>
        <pubmed_id>10883409</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Frovatriptan</name>
        <accession>HMDB15133</accession>
      </metabolite>
      <reference>
        <reference_text>Markus F, Mikko K: Frovatriptan review.  Expert Opin Pharmacother. 2007 Dec;8(17):3029-33.</reference_text>
        <pubmed_id>18001261</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Frovatriptan</name>
        <accession>HMDB15133</accession>
      </metabolite>
      <reference>
        <reference_text>Balbisi EA: Frovatriptan: a review of pharmacology, pharmacokinetics and clinical potential in the treatment of menstrual migraine. Ther Clin Risk Manag. 2006 Sep;2(3):303-8.</reference_text>
        <pubmed_id>18360605</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Frovatriptan</name>
        <accession>HMDB15133</accession>
      </metabolite>
      <reference>
        <reference_text>Elkind AH, Wade A, Ishkanian G: Pharmacokinetics of frovatriptan in adolescent migraineurs.  J Clin Pharmacol. 2004 Oct;44(10):1158-65.</reference_text>
        <pubmed_id>15342617</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Frovatriptan</name>
        <accession>HMDB15133</accession>
      </metabolite>
      <reference>
        <reference_text>Buchan P, Wade A, Ward C, Oliver SD, Stewart AJ, Freestone S: Frovatriptan: a review of drug-drug interactions.  Headache. 2002 Apr;42 Suppl 2:S63-73.</reference_text>
        <pubmed_id>12028322</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pergolide</name>
        <accession>HMDB15317</accession>
      </metabolite>
      <reference>
        <reference_text>Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists.  Curr Top Med Chem. 2008;8(12):1049-67.</reference_text>
        <pubmed_id>18691132</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pergolide</name>
        <accession>HMDB15317</accession>
      </metabolite>
      <reference>
        <reference_text>Lam YW: Clinical pharmacology of dopamine agonists.  Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S.</reference_text>
        <pubmed_id>10641988</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bromocriptine</name>
        <accession>HMDB15331</accession>
      </metabolite>
      <reference>
        <reference_text>Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists.  Curr Top Med Chem. 2008;8(12):1049-67.</reference_text>
        <pubmed_id>18691132</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bromocriptine</name>
        <accession>HMDB15331</accession>
      </metabolite>
      <reference>
        <reference_text>Lam YW: Clinical pharmacology of dopamine agonists.  Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S.</reference_text>
        <pubmed_id>10641988</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aripiprazole</name>
        <accession>HMDB05042</accession>
      </metabolite>
      <reference>
        <reference_text>Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11.</reference_text>
        <pubmed_id>17848919</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Yohimbine</name>
        <accession>HMDB15464</accession>
      </metabolite>
      <reference>
        <reference_text>Millan MJ, Newman-Tancredi A, Audinot V, Cussac D, Lejeune F, Nicolas JP, Coge F, Galizzi JP, Boutin JA, Rivet JM, Dekeyne A, Gobert A: Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states. Synapse. 2000 Feb;35(2):79-95.</reference_text>
        <pubmed_id>10611634</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Yohimbine</name>
        <accession>HMDB15464</accession>
      </metabolite>
      <reference>
        <reference_text>Kaumann AJ: Yohimbine and rauwolscine inhibit 5-hydroxytryptamine-induced contraction of large coronary arteries of calf through blockade of 5 HT2 receptors. Naunyn Schmiedebergs Arch Pharmacol. 1983 Jun;323(2):149-54.</reference_text>
        <pubmed_id>6136920</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bopindolol</name>
        <accession>HMDB15696</accession>
      </metabolite>
      <reference>
        <reference_text>Dawson LA, Nguyen HQ: The role of 5-HT(1A) and 5-HT(1B/1D) receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: the mechanism of action of (+/-)pindolol. Neuropharmacology. 2000 Apr 3;39(6):1044-52.</reference_text>
        <pubmed_id>10727715</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bopindolol</name>
        <accession>HMDB15696</accession>
      </metabolite>
      <reference>
        <reference_text>Ariani K, Hamblin MW, Tan GL, Stratford CA, Ciaranello RD: G protein dependent alterations in [125I]iodocyanopindolol and +/- cyanopindolol binding at 5-HT1B binding sites in rat brain membranes. Neurochem Res. 1989 Sep;14(9):835-43.</reference_text>
        <pubmed_id>2512511</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bopindolol</name>
        <accession>HMDB15696</accession>
      </metabolite>
      <reference>
        <reference_text>Leonhardt S, Herrick-Davis K, Titeler M: Detection of a novel serotonin receptor subtype (5-HT1E) in human brain: interaction with a GTP-binding protein. J Neurochem. 1989 Aug;53(2):465-71.</reference_text>
        <pubmed_id>2664084</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bopindolol</name>
        <accession>HMDB15696</accession>
      </metabolite>
      <reference>
        <reference_text>Herrick-Davis K, Titeler M, Leonhardt S, Struble R, Price D: Serotonin 5-HT1D receptors in human prefrontal cortex and caudate: interaction with a GTP binding protein. J Neurochem. 1988 Dec;51(6):1906-12.</reference_text>
        <pubmed_id>3141589</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bopindolol</name>
        <accession>HMDB15696</accession>
      </metabolite>
      <reference>
        <reference_text>Terron JA, Lopez-Munoz FJ, Hong E, Villalon CM: 2-(2-Aminoethyl)-quinoline (D-1997): a novel agonist at 5-hydroxytryptamine1-like receptors in the canine basilar artery. Arch Int Pharmacodyn Ther. 1994 Jan-Feb;327(1):56-68.</reference_text>
        <pubmed_id>7944828</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
